Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
复制标题
DOI：
10.1136/jitc-2021-003956
复制
发表时间：
2022-05
影响因子：
10.9
通讯作者：
中科院分区：
文献类型：
--
作者：
近年来，免疫疗法改变了肺癌的治疗方式。免疫检查点抑制剂(ICIS)--无论是作为单一疗法，还是与其他ICIS或化疗联合使用--除了为部分经过深度治疗的非小细胞肺癌(NSCLC)患者提供持久的反应和延长生存结果外，还在晚期疾病的一线治疗、新辅助和辅助环境中以及其他胸部恶性肿瘤(如小细胞肺癌(SCLC)和间皮瘤)中显示出好处。然而，具有挑战性的问题仍然存在，包括治疗选择，基于适当生物标记物的患者识别谁可能受益，免疫疗法在特殊人群中的使用，如自身免疫性疾病患者，以及毒性管理。患者和照顾者的教育和对生活质量(QOL)的支持对于获得免疫治疗的最大好处也是重要的。为了就这些和其他重要问题向肿瘤界提供指导，癌症免疫治疗学会(SITC)召集了一个多学科专家小组来制定临床实践指南(CPG)。本CPG是对SITC 2018年关于免疫疗法治疗非小细胞肺癌的出版物的更新，并扩大到包括关于小细胞肺癌和间皮瘤的建议。专家小组利用已发表的文献和他们的临床经验，就肺癌和间皮瘤免疫治疗的这些重要方面向医护人员提出建议，包括诊断测试、治疗计划、免疫相关的不良事件和患者的生活质量考虑因素。本CPG中基于证据和共识的建议旨在为使用免疫疗法治疗肺癌或间皮瘤患者的癌症护理人员提供指导。
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or chemotherapy—have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small-cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC’s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.
登录
查看更多内容
DOI：
10.1200/jco.20.01605
发表时间：
2021-03-01
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Borghaei H;Gettinger S;Vokes EE;Chow LQM;Burgio MA;de Castro Carpeno J;Pluzanski A;Arrieta O;Frontera OA;Chiari R;Butts C;Wójcik-Tomaszewska J;Coudert B;Garassino MC;Ready N;Felip E;García MA;Waterhouse D;Domine M;Barlesi F;Antonia S;Wohlleber M;Gerber DE;Czyzewicz G;Spigel DR;Crino L;Eberhardt WEE;Li A;Marimuthu S;Brahmer J
通讯作者：
Brahmer J
影响因子：
4.6
作者：
Bonneville R;Krook MA;Kautto EA;Miya J;Wing MR;Chen HZ;Reeser JW;Yu L;Roychowdhury S
通讯作者：
Roychowdhury S
影响因子：
10.9
作者：
Brahmer JR;Govindan R;Anders RA;Antonia SJ;Sagorsky S;Davies MJ;Dubinett SM;Ferris A;Gandhi L;Garon EB;Hellmann MD;Hirsch FR;Malik S;Neal JW;Papadimitrakopoulou VA;Rimm DL;Schwartz LH;Sepesi B;Yeap BY;Rizvi NA;Herbst RS
通讯作者：
Herbst RS
影响因子：
7.4
作者：
Carbone M;Ferris LK;Baumann F;Napolitano A;Lum CA;Flores EG;Gaudino G;Powers A;Bryant-Greenwood P;Krausz T;Hyjek E;Tate R;Friedberg J;Weigel T;Pass HI;Yang H
通讯作者：
Yang H
影响因子：
5.3
作者：
CELLA, DF;BONOMI, AE;BONOMI, P
通讯作者：
BONOMI, P